IRTC

$117.53

Post-MarketAs of Mar 17, 8:00 PM UTC

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.

Recent News

Simply Wall St.
Mar 2, 2026

How The iRhythm Holdings (IRTC) Story Is Shifting As Targets Reset And Guidance Holds

Analysts have trimmed their modelled fair value estimate for iRhythm Holdings from US$221.27 to US$212.87, a reduction of about 3.8% in the implied price target. This shift lines up with recent commentary in which several firms are cutting targets, even as they acknowledge Q4 revenue of US$208.9m, reaffirmed 2026 guidance, and progress with offerings like ZioAT and channel partnerships. As you read on, you will see how both bullish and cautious voices are shaping the evolving story around...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 2, 2026

iRhythm Holdings, Inc. (IRTC) Reports $5.6M Net Income, 70.9% Gross Margin in Q4 2025

iRhythm Holdings, Inc. (NASDAQ:IRTC) is among the 10 Fastest Growing Mid Cap Stocks to Buy Now. iRhythm Holdings, Inc. (NASDAQ:IRTC) is one of the fastest growing stocks. TheFly reported on February 23 that Goldman Sachs reduced its price target on IRTC to $184 from $211 and maintained a Neutral rating on the stock. On February […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.
StockStory
Feb 27, 2026

Evolent Health and iRhythm Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Feb 23, 2026

iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics Stocks Trade Down, What You Need To Know

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 20, 2026

iRhythm Technologies, Inc. Q4 2025 Earnings Call Summary

Moby summary of iRhythm Technologies, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.